Combination Chemotherapy in Treating Children With Lymphoma

Key facts

Sponsor

Children's Oncology Group

Principal Investigator

Minnie Abromowitch, MD

Children's Hospital Medical Center, Cincinnati

Intervention

filgrastim(biological)

Enrollment

221 enrolled

Eligibility

20 years · All sexes

Timeline

1994 – 2007

Study locations (30)

• Long Beach Memorial Medical Center, Long Beach, California, United States
• Children's Hospital Los Angeles, Los Angeles, California, United States
• Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
• Children's Hospital of Orange County, Orange, California, United States
• UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
• Children's Hospital of Denver, Denver, Colorado, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• University of Chicago Cancer Research Center, Chicago, Illinois, United States
• Indiana University Cancer Center, Indianapolis, Indiana, United States
• University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
• University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
• Mayo Clinic Cancer Center, Rochester, Minnesota, United States
• Children's Mercy Hospital, Kansas City, Missouri, United States
• University of Nebraska Medical Center, Omaha, Nebraska, United States
• St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Anaplastic large cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06561048
  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
  Corvus Pharmaceuticals, Inc.
• RECRUITINGPHASE1NCT06494371
  A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
  Ruijin Hospital
• RECRUITINGPHASE1, PHASE2NCT06137144
  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
  AstraZeneca
• ACTIVE NOT RECRUITINGPHASE1NCT04526834
  Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
  Tessa Therapeutics
• ACTIVE NOT RECRUITINGPHASE3NCT04881838
  CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL
  Children's Cancer Group, China
• ACTIVE NOT RECRUITINGPHASE2NCT02978625
  Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
  National Cancer Institute (NCI)
• RECRUITINGNCT04220970
  Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
  The Lymphoma Academic Research Organisation

See all trials for Anaplastic large cell lymphoma →